Alpha Cognition Inc. (ACOGF)
USD 5.73
(N/A%)
USD 5.73
(N/A%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 7.16 Million USD | 67.75% |
| 2022 | 4.27 Million USD | 10.92% |
| 2021 | 3.85 Million USD | -54.27% |
| 2020 | 8.42 Million USD | 631.12% |
| 2019 | 1.15 Million USD | 4447.47% |
| 2018 | 25.32 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.47 Million USD | 5.54% |
| 2024 Q1 | 3.29 Million USD | -54.04% |
| 2023 Q4 | 7.16 Million USD | -8.59% |
| 2023 FY | 7.16 Million USD | 67.75% |
| 2023 Q3 | 7.83 Million USD | 228.47% |
| 2023 Q2 | 2.38 Million USD | -27.9% |
| 2023 Q1 | 3.3 Million USD | -22.52% |
| 2022 Q4 | 4.27 Million USD | 58.68% |
| 2022 FY | 4.27 Million USD | 10.92% |
| 2022 Q2 | 2.67 Million USD | -30.13% |
| 2022 Q1 | 3.83 Million USD | -0.49% |
| 2022 Q3 | 2.69 Million USD | 0.53% |
| 2021 Q3 | 4.94 Million USD | -34.05% |
| 2021 Q2 | 7.49 Million USD | -21.34% |
| 2021 Q1 | 9.52 Million USD | 1063.44% |
| 2021 Q4 | 3.85 Million USD | -22.09% |
| 2021 FY | 3.85 Million USD | -54.27% |
| 2020 Q3 | 9.52 Million USD | 0.0% |
| 2020 FY | 8.42 Million USD | 631.12% |
| 2020 Q4 | 818.95 Thousand CAD | -91.4% |
| 2019 Q4 | 1.15 Million USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 FY | 33.63 Thousand USD | 4447.47% |
| 2018 FY | 25.32 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 72.47 Million USD | 90.114% |
| Neon Bloom, Inc. | 1.22 Million USD | -484.301% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -785.859% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -15930.012% |
| Qrons Inc. | 1.48 Million USD | -381.273% |
| Rebus Holdings, Inc. | 5.24 Million USD | -36.68% |
| Skye Bioscience, Inc. | 14.07 Million USD | 49.086% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 87.859% |
| Adynxx, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 90.437% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -3462.508% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 24.31% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -26017.355% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 86.559% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 25.227% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1599.554% |
| SQZ Biotechnologies Company | 50.03 Million USD | 85.682% |
| Intellipharmaceutics International Inc. | 12 Million USD | 40.337% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -86.029% |
| Mesoblast Limited | 188.44 Million USD | 96.198% |
| Marizyme, Inc. | 26.67 Million USD | 73.141% |
| Genus plc | 485 Million USD | 98.523% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -22.629% |
| Pharming Group N.V. | 244.07 Million USD | 97.064% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -256.433% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -184.731% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -88.547% |
| ContraFect Corporation | 32.53 Million USD | 77.976% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -261.618% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -87.185% |
| IMV Inc. | 37.93 Million USD | 81.112% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 39.169% |
| MultiCell Technologies, Inc. | 1617.67 USD | -442807.021% |
| ONE Bio Corp. | 27.49 Million USD | 73.942% |
| Accustem Sciences Inc. | 1.07 Million USD | -563.873% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 90.745% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -238.749% |
| Q BioMed Inc. | 8.13 Million USD | 11.904% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 91.361% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -39.229% |
| Biomind Labs Inc. | 1.49 Million USD | -378.094% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 93.965% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 20.763% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 61.068% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -399.684% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -4942.242% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -24.695% |
| GB Sciences, Inc. | 5.41 Million USD | -32.251% |
| HST Global, Inc. | 593.59 Thousand USD | -1107.018% |
| CSL Limited | 18.62 Billion USD | 99.962% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -468.997% |
| Halberd Corporation | 728.71 Thousand USD | -883.201% |
| Enzolytics Inc. | 365.26 Million USD | 98.038% |
| Agentix Corp. | 2.51 Million USD | -185.386% |
| Resverlogix Corp. | 67.39 Million USD | 89.369% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -754.239% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 98.39% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -318.015% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 71.047% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 39.808% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -95.483% |
| AVAX Technologies, Inc. | 3.99 Million USD | -79.4% |
| Zenith Capital Corp. | 27.56 Thousand USD | -25888.516% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.46% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -2902.16% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -91.864% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -952.353% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -164.223% |
| Kadimastem Ltd | 3.5 Million USD | -104.424% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -10605.037% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 85.746% |
| BioStem Technologies, Inc. | 15.9 Million USD | 54.952% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1441.81% |
| LadRx Corporation | 2.2 Million USD | -225.593% |
| Cell Source, Inc. | 15.8 Million USD | 54.673% |
| Regen BioPharma, Inc. | 5.45 Million USD | -31.28% |
| Regen BioPharma, Inc. | 5.45 Million USD | -31.28% |
| NovAccess Global Inc. | 7.86 Million USD | 8.854% |
| Affymax, Inc. | 8.87 Million USD | 19.234% |
| Itoco Inc. | 1.65 Million USD | -333.401% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -249.235% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -18.446% |
| Mobile Lads Corp. | 1.31 Million USD | -445.473% |
| CytoDyn Inc. | 127.89 Million USD | 94.398% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -17041.018% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -357.411% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 35.133% |
| SYBLEU INC | 681.41 Thousand USD | -951.458% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -17.419% |
| International Stem Cell Corporation | 5.27 Million USD | -35.774% |
| Bioxytran, Inc. | 3.24 Million USD | -120.489% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1044.882% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -55.178% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 82.523% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 67.82% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -253.748% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -30.792% |
| Neutra Corp. | 973.52 Thousand USD | -635.959% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 75.307% |
| PureTech Health plc | 125.58 Million USD | 94.295% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -90.698% |
| IXICO plc | 1.9 Million USD | -277.035% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 65.099% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 93.066% |
| CSL Limited | 18.62 Billion USD | 99.962% |
| Cellectis S.A. | 249.36 Million USD | 97.127% |